Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

GUBamy had an 11-day half-life and a pharmacokinetic profile that supports once ... a combination of long-acting amylin ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Wave Life Sciences Ltd. (NASDAQ:WVE ... to unlock the next frontier in obesity treatment and address the millions impacted by ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs ... 36 days in a phase 1 readout in September. Metsera has ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.